Low concentrations of ethanol protect against synaptotoxicity induced by Aβ in hippocampal neurons

Neurobiology of Aging

Volumn 36, Issue 2, 2015, Pages 845-856

  Muñoz, Gonzalo ^a   Urrutia, Juan C ^a   Burgos, Carlos F ^a   Silva, Viviana ^b   Aguilar, Felipe ^b   Sama, Michelle ^c   Yeh, Hermes H ^c   Opazo, Carlos ^d   Aguayo, Luis G ^a  

^a UNIVERSITY OF CONCEPCIÓN   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE VALPARAÍSO   (Chile)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Alzheimer's disease; A ; Ethanol neuroprotection; Synaptotoxicity

Indexed keywords

AMYLOID BETA PROTEIN; ALCOHOL; NEUROPROTECTIVE AGENT;

ALCOHOL CONSUMPTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CELL; CONTROLLED STUDY; DOWN REGULATION; ELECTRON MICROSCOPY; EMBRYO; HIPPOCAMPUS; LATENT PERIOD; LEARNING; MOLECULAR DOCKING; MOUSE; NERVE CELL MEMBRANE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PATCH CLAMP TECHNIQUE; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN LIPID INTERACTION; RAT; SYNAPTOTOXICITY; WORKING MEMORY; ALZHEIMER DISEASE; ANIMAL; CELL CULTURE; DOSE RESPONSE; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHANOL; HIPPOCAMPUS; MICE, TRANSGENIC; NEUROPROTECTIVE AGENTS; RATS, SPRAGUE-DAWLEY;

EID: 84922762224     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.10.017     Document Type: Article

References (59)

1. Balasubramanian S.V., Campbell R.B., Straubinger R.M. Propofol, a general anesthetic, promotes the formation of fluid phase domains in model membranes. Chem. Phys. Lipids 2002, 114:35-44.
2. Bate C., Williams A. Ethanol protects cultured neurons against amyloid-beta and alpha-synuclein-induced synapse damage. Neuropharmacology 2011, 61:1406-1412.
3. Belmadani A., Kumar S., Schipma M., Collins M.A., Neafsey E.J. Inhibition of amyloid-beta-induced neurotoxicity and apoptosis by moderate ethanol preconditioning. Neuroreport 2004, 15:2093-2096.
4. Collins M.A., Neafsey E.J., Wang K., Achille N.J., Mitchell R.M., Sivaswamy S. Moderate ethanol preconditioning of rat brain cultures engenders neuroprotection against dementia-inducing neuroinflammatory proteins: possible signaling mechanisms. Mol. Neurobiol. 2010, 41:420-425.
5. Chauhan A., Ray I., Chauhan V.P. Interaction of amyloid beta-protein with anionic phospholipids: possible involvement of Lys28 and C-terminus aliphatic amino acids. Neurochem. Res. 2000, 25:423-429.
6. Desy O., Carignan D., de Campos-Lima P.O. Short-term immunological effects of non-ethanolic short-chain alcohols. Toxicol. Lett. 2012, 210:44-52.
7. Diaz J.C., Linnehan J., Pollard H., Arispe N. Histidines 13 and 14 in the Abeta sequence are targets for inhibition of Alzheimer's disease Abeta ion channel and cytotoxicity. Biol. Res. 2006, 39:447-460.
8. Dzwolak W., Grudzielanek S., Smirnovas V., Ravindra R., Nicolini C., Jansen R., Loksztejn A., Porowski S., Winter R. Ethanol-perturbed amyloidogenic self-assembly of insulin: looking for origins of amyloid strains. Biochemistry 2005, 44:8948-8958.
9. Faber-Langendoen K., Morris J.C., Knesevich J.W., LaBarge E., Miller J.P., Berg L. Aphasia in senile dementia of the Alzheimer type. Ann. Neurol. 1988, 23:365-370.
10. Galasko D.R., Graff-Radford N., May S., Hendrix S., Cottrell B.A., Sagi S.A., Mather G., Laughlin M., Zavitz K.H., Swabb E., Golde T.E., Murphy M.P., Koo E.H. Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals. Alzheimer Dis. Assoc. Disord. 2007, 21:292-299.
11. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., Eisner L., Kirby L., Rovira M.B., Forette F., Orgogozo J.M. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64:1553-1562.
12. Grosdidier A., Zoete V., Michielin O. SwissDock, a protein-small molecule docking web service based on EADock DSS. Nucleic Acids Res. 2011, 39(Web Server issue):W270-W277.
13. Hicks J.B., Lai Y., Sheng W., Yang X., Zhu D., Sun G.Y., Lee J.C. Amyloid-beta peptide induces temporal membrane biphasic changes in astrocytes through cytosolic phospholipase A2. Biochim. Biophys. Acta 2008, 1778:2512-2519.
14. Hirota N., Mizuno K., Goto Y. Group additive contributions to the alcohol-induced alpha-helix formation of melittin: implication for the mechanism of the alcohol effects on proteins. J.Mol. Biol. 1998, 275:365-378.
15. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
16. Hsieh H., Boehm J., Sato C., Iwatsubo T., Tomita T., Sisodia S., Malinow R. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 2006, 52:831-843.
17. Hughes S.R., Goyal S., Sun J.E., Gonzalez-DeWhitt P., Fortes M.A., Riedel N.G., Sahasrabudhe S.R. Two-hybrid system as a model to study the interaction of beta-amyloid peptide monomers. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:2065-2070.
18. Jang H., Arce F.T., Capone R., Ramachandran S., Lal R., Nussinov R. Misfolded amyloid ion channels present mobile beta-sheet subunits in contrast to conventional ion channels. Biophys. J. 2009, 97:3029-3037.
19. Kawahara M. Neurotoxicity of beta-amyloid protein: oligomerization, channel formation, and calcium dyshomeostasis. Curr. Pharm. Des. 2010, 16:2779-2789.
20. Klemm W.R. Biological water and its role in the effects of alcohol. Alcohol 1998, 15:249-267.
21. Koopmans G., Blokland A., van Nieuwenhuijzen P., Prickaerts J. Assessment of spatial learning abilities of mice in a new circular maze. Physiol. Behav. 2003, 79:683-693.
22. Kwon Y.E., Park J.Y., No K.T., Shin J.H., Lee S.K., Eun J.S., Yang J.H., Shin T.Y., Kim D.K., Chae B.S., Leem J.Y., Kim K.H. Synthesis, invitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abeta1-42 aggregation for Alzheimer's disease therapeutics. Bioorg. Med. Chem. 2007, 15:6596-6607.
23. Lal R., Lin H., Quist A.P. Amyloid beta ion channel: 3D structure and relevance to amyloid channel paradigm. Biochim. Biophys. Acta 2007, 1768:1966-1975.
24. Lin S.Y., Li M.J., Wei Y.S. Ethanol or/and captopril-induced precipitation and secondary conformational changes of human serum albumin. Spectrochim Acta A Mol. Biomol. Spectrosc. 2004, 60:3107-3111.
25. Luchsinger J.A., Mayeux R. Dietary factors and Alzheimer's disease. Lancet Neurol. 2004, 3:579-587.
26. Luhrs T., Ritter C., Adrian M., Riek-Loher D., Bohrmann B., Dobeli H., Schubert D., Riek R. 3D structure of Alzheimer's amyloid-beta(1-42) fibrils. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:17342-17347.
27. Mason R.P., Jacob R.F., Walter M.F., Mason P.E., Avdulov N.A., Chochina S.V., Igbavboa U., Wood W.G. Distribution and fluidizing action of soluble and aggregated amyloid beta-peptide in rat synaptic plasma membranes. J.Biol. Chem. 1999, 274:18801-18807.
28. Matulis D., Lovrien R. 1-Anilino-8-naphthalene sulfonate anion-protein binding depends primarily on ion pair formation. Biophys. J. 1998, 74:422-429.
29. Mohs R.C. Aperspective on risks that impede development of drugs to modify the course of Alzheimer's disease: can they be reduced?. Alzheimers Dement. 2008, 4(1 Suppl 1):S85-S87.
30. Mukamal K.J., Kuller L.H., Fitzpatrick A.L., Longstreth W.T., Mittleman M.A., Siscovick D.S. Prospective study of alcohol consumption and risk of dementia in older adults. JAMA 2003, 289:1405-1413.
31. Muller W.E., Koch S., Eckert A., Hartmann H., Scheuer K. beta-Amyloid peptide decreases membrane fluidity. Brain Res. 1995, 674:133-136.
32. Neafsey E.J., Collins M.A. Moderate alcohol consumption and cognitive risk. Neuropsychiatr. Dis. Treat. 2011, 7:465-484.
33. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003, 39:409-421.
34. Parasassi T., De Stasio G., d'Ubaldo A., Gratton E. Phase fluctuation in phospholipid membranes revealed by Laurdan fluorescence. Biophys. J. 1990, 57:1179-1186.
35. Parasassi T., Di Stefano M., Ravagnan G., Sapora O., Gratton E. Membrane aging during cell growth ascertained by Laurdan generalized polarization. Exp. Cell Res. 1992, 202:432-439.
36. Parodi J., Sepulveda F.J., Roa J., Opazo C., Inestrosa N.C., Aguayo L.G. Beta-amyloid causes depletion of synaptic vesicles leading to neurotransmission failure. J.Biol. Chem. 2010, 285:2506-2514.
37. Peters R., Peters J., Warner J., Beckett N., Bulpitt C. Alcohol, dementia and cognitive decline in the elderly: a systematic review. Age Ageing 2008, 37:505-512.
38. Quist A., Doudevski I., Lin H., Azimova R., Ng D., Frangione B., Kagan B., Ghiso J., Lal R. Amyloid ion channels: a common structural link for protein-misfolding disease. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:10427-10432.
39. Ruitenberg A., van Swieten J.C., Witteman J.C., Mehta K.M., van Duijn C.M., Hofman A., Breteler M.M. Alcohol consumption and risk of dementia: the Rotterdam Study. Lancet 2002, 359:281-286.
40. Selkoe D.J. Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. J.Clin. Invest. 2002, 110:1375-1381.
41. Sepulveda F.J., Fierro H., Fernandez E., Castillo C., Peoples R.W., Opazo C., Aguayo L.G. Nature of the neurotoxic membrane actions of amyloid-beta on hippocampal neurons in Alzheimer's disease. Neurobiol. Aging 2014, 35:472-481.
42. Sepulveda F.J., Parodi J., Peoples R.W., Opazo C., Aguayo L.G. Synaptotoxicity of Alzheimer beta amyloid can be explained by its membrane perforating property. PLoS One 2010, 5:e11820.
43. Shankar G.M., Bloodgood B.L., Townsend M., Walsh D.M., Selkoe D.J., Sabatini B.L. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J.Neurosci. 2007, 27:2866-2875.
44. Shankar G.M., Li S., Mehta T.H., Garcia-Munoz A., Shepardson N.E., Smith I., Brett F.M., Farrell M.A., Rowan M.J., Lemere C.A., Regan C.M., Walsh D.M., Sabatini B.L., Selkoe D.J. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 2008, 14:837-842.
45. Shanmugam G., Polavarapu P.L. Structure of A beta(25-35) peptide in different environments. Biophys. J. 2004, 87:622-630.
46. Shao Q., Fan Y., Yang L., Gao Y.Q. From protein denaturant to protectant: comparative molecular dynamics study of alcohol/protein interactions. J.Chem. Phys. 2012, 136:115101.
47. Shen C.L., Murphy R.M. Solvent effects on self-assembly of beta-amyloid peptide. Biophys. J. 1995, 69:640-651.
48. Siemers E.R., Dean R.A., Friedrich S., Ferguson-Sells L., Gonzales C., Farlow M.R., May P.C. Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clin. Neuropharmacol. 2007, 30:317-325.
49. Sonmez M., Ince H.Y., Yalcin O., Ajdzanovic V., Spasojevic I., Meiselman H.J., Baskurt O.K. The effect of alcohols on red blood cell mechanical properties and membrane fluidity depends on their molecular size. PLoS One 2013, 8:e76579.
50. Spires T.L., Hyman B.T. Transgenic models of Alzheimer's disease: learning from animals. NeuroRx 2005, 2:423-437.
51. Standridge J.B. Pharmacotherapeutic approaches to the prevention of Alzheimer's disease. Am. J. Geriatr. Pharmacother. 2004, 2:119-132.
52. Tapia J.C., Aguilar L.F., Sotomayor C.P., Aguayo L.G. Ethanol affects the function of a neurotransmitter receptor protein without altering the membrane lipid phase. Eur. J. Pharmacol. 1998, 354:239-244.
53. Tapia J.C., Mentis G.Z., Navarrete R., Nualart F., Figueroa E., Sánchez A., Aguayo L.G. Early expression of glycine and GABAA receptors in developing spinal cord neurons. Effects on neurite outgrowth. Neuroscience 2001, 108:493-506.
54. Tjernberg L.O., Naslund J., Lindqvist F., Johansson J., Karlstrom A.R., Thyberg J., Terenius L., Nordstedt C. Arrest of beta-amyloid fibril formation by a pentapeptide ligand. J.Biol. Chem. 1996, 271:8545-8548.
55. Turner P.R., O'Connor K., Tate W.P., Abraham W.C. Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog. Neurobiol. 2003, 70:1-32.
56. Verbaten M.N. Chronic effects of low to moderate alcohol consumption on structural and functional properties of the brain: beneficial or not?. Hum. Psychopharmacol. 2009, 24:199-205.
57. Wang J., Ho L., Zhao Z., Seror I., Humala N., Dickstein D.L., Thiyagarajan M., Percival S.S., Talcott S.T., Pasinetti G.M. Moderate consumption of Cabernet Sauvignon attenuates Abeta neuropathology in a mouse model of Alzheimer's disease. FASEB J. 2006, 20:2313-2320.
58. Waschuk S.A., Elton E.A., Darabie A.A., Fraser P.E., McLaurin J.A. Cellular membrane composition defines Abeta-lipid interactions. J.Biol. Chem. 2001, 276:33561-33568.
59. Yevenes G.E., Peoples R.W., Tapia J.C., Parodi J., Soto X., Olate J., Aguayo L.G. Modulation of glycine-activated ion channel function by G-protein betagamma subunits. Nat. Neurosci. 2003, 6:819-824.